ArticleDiabetes care2012
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes.
Article in Diabetes care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 46 citations in OpenAlex.
- Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects.Clinical drug investigation · 2022Trial
- Single-dose euglycaemic clamp studies demonstrating pharmacokinetic and pharmacodynamic similarity between MK-1293 insulin glargine and originator insulin glargine (Lantus) in subjects with type 1 diabetes and healthy subjects.Diabetes, obesity & metabolism · 2018Trial
- Influence of insulin and glargine on outgrowth and number of circulating endothelial progenitor cells in type 2 diabetes patients: a partially double-blind, randomized, three-arm unicenter study.Cardiovascular diabetology · 2014Trial
- Trial
- Trial
- The Silver Jubilee (2025) of Insulin Glargine: Introducing the Era of Long-Acting Insulin Analogues for Diabetes Mellitus.Diabetes, obesity & metabolism · 2026Review
- The Modern Role of Basal Insulin in Advancing Therapy in People With Type 2 Diabetes.Diabetes care · 2025Review
- A comparative evaluation of bioequivalence of Gan & Lee glargine U300 and ToujeoFrontiers in endocrinology · 2024Article
- Pharmacokinetics and Safety of iGlarLixi in Healthy Chinese Participants: Results of a Phase 1 Randomized Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Insulin: evolution of insulin formulations and their application in clinical practice over 100 years.Acta diabetologica · 2022Review
- Pharmacokinetic and pharmacodynamic similarity evaluation between an insulin glargine biosimilar product and LantusFrontiers in pharmacology · 2022Article
- Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions.Artificial organs · 2021Review
- Equipotency of insulin glargine 300 and 100 U/mL with intravenous dosing but differential bioavailability with subcutaneous dosing in dogs.Diabetes, obesity & metabolism · 2021Article
- Co-Managing Patients with Type 1 Diabetes and Cancer.Current diabetes reports · 2016Review
- rDNA insulin glargine U300 - a critical appraisal.Diabetes, metabolic syndrome and obesity : targets and therapy · 2016Review
- Use of Insulin Lispro Protamine Suspension in Pregnancy.Advances in therapy · 2015Review
- Insulin therapy and cancer.Diabetes care · 2013Review
- Differences in metabolic and mitogenic signallingof insulin glargine and AspB10 human insulin in rats [corrected].Diabetologia · 2013Article
- The metabolic and mitogenic properties of basal insulin analogues.Archives of physiology and biochemistry · 2013Review
- Glargine and cancer: can we now suggest closure?Diabetes care · 2012Article
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate concentration of plasma insulin glargine after its subcutaneous dosing compared with concentration of its metabolites 1 (M1) and 2 (M2) in subjects with type 2 diabetes. RESEARCH DESIGN AND
methodsNine subjects underwent a 32-h euglycemic glucose clamp study (0.4 units/kg glargine after 1 week of daily glargine administration). Glargine, M1, and M2 were measured by a specific liquid chromatography-tandem mass spectrometry assay.
resultsGlargine was detected in only five of the nine subjects, at few time points, and at negligible concentrations. M1 was detected in all subjects and exhibited the same pattern as traditional radioimmunoassay-measured plasma insulin. M2 was not detected at all.
conclusionsAfter subcutaneous injection, glargine was minimally detectable in blood, whereas its metabolite M1 accounted for most (>90%) of the plasma insulin concentration and metabolic action of the injected glargine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.